Exact Sciences Corporation

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Exact Sciences Corporation sits in the top decile of US sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count).

30 total trials 3 currently recruiting 19 completed top decile by trial count

Exact Sciences Corporation: 30 sponsored US clinical trials, 3 recruiting.

Exact Sciences Corporation sponsors 30 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 19 completed. The most-studied condition in this pipeline is Colorectal Cancer, with 4 trials.

Top-decile sponsor footprint

Exact Sciences Corporation ranks in the top decile of sponsors by registered trial count (#538 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 37/100

19 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

30 total, page 1 of 1

RECRUITING

Endometrial Cancer Vaginal Fluid Specimen Collection Study

NCT07544680

RECRUITING

Falcon Real World Evidence Registry

NCT06589310

RECRUITING

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

NCT06401421

ACTIVE NOT RECRUITING

CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

NCT05210283

ACTIVE NOT RECRUITING

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

NCT05064553

ACTIVE NOT RECRUITING

Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality

NCT04124406

TERMINATED

Informed Choice - Compass

NCT05246839

COMPLETED

Stool Collection Sub-Study of Exact Sciences Protocol 2018-01

NCT04473625

COMPLETED

Home Usability Study of the SARS-CoV-2 (COVID-19) Test

NCT04395391

COMPLETED

Detecting Cancers Earlier Through Elective Plasma-based CancerSEEK Testing

NCT04213326

COMPLETED

Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"

NCT04144738

COMPLETED

Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C"

NCT04144751

TERMINATED

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

NCT03727087

COMPLETED

Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold

NCT03821948

COMPLETED

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

NCT03789162

TERMINATED

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies

NCT03727009

COMPLETED

Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.

NCT03741166

COMPLETED

An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now

NCT03728348

TERMINATED

Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)

NCT03705013

COMPLETED

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

NCT03662204

COMPLETED

Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma

NCT03628651

COMPLETED

Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program

NCT03628638

COMPLETED

Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer

NCT03633006

COMPLETED

A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval

NCT02419716

TERMINATED

Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers

NCT02503631

COMPLETED

Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

NCT02503696

COMPLETED

Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease

NCT01819766

COMPLETED

Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing

NCT01600209

COMPLETED

Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

NCT01397747

COMPLETED

Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

NCT01260168

What is open in the Exact Sciences Corporation pipeline

3 recruiting of 30 indexed (10% open); 19 completed (63%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Colorectal Cancer (4 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Exact Sciences Corporation: open-pipeline peers nationwide

Peers matched on 30 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Exact Sciences Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 5101520253035 0%5%10%15%20% Total trials Recruiting share Exact Sciences CorporationBiotronikCharles Drew University of Medicine and ScienceChiesi Farmaceutici S.p.A.Debiopharm InternationalAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Exact Sciences Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Exact Sciences Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 30 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this Exact Sciences Corporation page

30 registered trials is a research-attention snapshot, not an endorsement of Exact Sciences Corporation or any single study.

  • 3 of Exact Sciences Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Colorectal Cancer is the condition Exact Sciences Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Colorectal Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Exact Sciences Corporation pipeline card: 30 registered trials from official public datasets.Report a data error.